Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

440 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men.
Veldhuis JD, Bidlingmaier M, Anderson SM, Wu Z, Strasburger CJ. Veldhuis JD, et al. Among authors: anderson sm. J Clin Endocrinol Metab. 2001 Jul;86(7):3304-10. doi: 10.1210/jcem.86.7.7656. J Clin Endocrinol Metab. 2001. PMID: 11443205 Clinical Trial.
Continuous 24-hour intravenous infusion of recombinant human growth hormone (GH)-releasing hormone-(1-44)-amide augments pulsatile, entropic, and daily rhythmic GH secretion in postmenopausal women equally in the estrogen-withdrawn and estrogen-supplemented states.
Evans WS, Anderson SM, Hull LT, Azimi PP, Bowers CY, Veldhuis JD. Evans WS, et al. Among authors: anderson sm. J Clin Endocrinol Metab. 2001 Feb;86(2):700-12. doi: 10.1210/jcem.86.2.7195. J Clin Endocrinol Metab. 2001. PMID: 11158034
Estradiol supplementation in postmenopausal women doubles rebound-like release of growth hormone (GH) triggered by sequential infusion and withdrawal of somatostatin: evidence that estrogen facilitates endogenous GH-releasing hormone drive.
Veldhuis JD, Anderson SM, Patrie JT, Bowers CY. Veldhuis JD, et al. Among authors: anderson sm. J Clin Endocrinol Metab. 2004 Jan;89(1):121-7. doi: 10.1210/jc.2003-031291. J Clin Endocrinol Metab. 2004. PMID: 14715838 Clinical Trial.
440 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page